Glioblastoma is a aggressive brain cancer known for its quick growth and unresponsiveness to conventional treatments. Studies are constantly underway to identify new management strategies, and recently, a new biomarker named LCA168 has emerged as a potential focus for glioblastoma treatment. LCA168 is a protein that is overexpressed in GBM cells c